The outcomes of this trial help confirm that cisplatin chemotherapy given adjuvantly with radiotherapy is not a superior alternative ,” said Sang Young Ryu, MD.

MS patients may receive less frequent rituximab infusions without increasing their chances of relapse or disease progression, ...

The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic ...

At ACC 2025, new real-world safety data were presented on sotatercept, a novel fusion protein for pulmonary arterial ...

A proteasome inhibitor, Boruzu references branded Velcade, a lyophilised powder that requires reconstitution prior to usage.

XFOR READ THE FULL XFOR RESEARCH REPORT Business Update Full Enrollment of Phase 3 4WARD Trial Expected in 2H25 X4 ...

A seven-year-old from Albrighton got on her bike to raise over £4,000 for charity to help provide a new look for sick young ...

Q4 2024 Earnings Call Transcript March 25, 2025 X4 Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0 ...

Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line ...

MNV-201 is also being studied in a Phase Ib for low-risk Myelodysplastic Syndrome; Preliminary clinical data demonstrate safety and efficacy HAIFA, Israel, (GLOBE NEWSWIRE) -- Minovia Therapeutics ...

X4 Pharmaceuticals announced that its Phase 3 4WARD trial for chronic neutropenia is now active at around 90% of targeted sites, with expected full enrollment by Q3 or Q4 of 2025 and top-line data ...

Indivior, leader in opioid treatment, trades near 52-week lows. Read more on INDV stock's financials, growth challenges, and ...